Nemaura Medical Inc. is a medical technology company. It engages in developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R), BEAT(TM) diabetes, and proBEAT(TM). SugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor. Nemaura Medical Inc. is based in New York, United States.
| Revenue (Most Recent Fiscal Year) | $0.08M |
| Net Income (Most Recent Fiscal Year) | $-14.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 40.35M |
| Free Float | 24.04M |
| Market Capitalization | $0.01M |
| Average Volume (Last 20 Days) | 7483.05 |
| Beta (Past 60 Months) | 0.82 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 40.42% |
| Percentage Held By Institutions (Latest 13F Reports) | 4.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |